Fosun Pharma: Controlled subsidiary drug granted clinical trial approval.

Fosun Pharma announced on March 16th that its holding subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., and its holding subsidiary have received approval from the National Medical Products Administration to conduct clinical trials of HLX07 in combination with Sultiluminab for the treatment of advanced squamous non-small cell lung cancer. After meeting the necessary conditions, Fuhong Hanlin plans to conduct relevant clinical studies of this treatment plan in China. As of the announcement date, there is no similar combination therapy approved for marketing worldwide.